Remicade Leukemia Association. Our Remicade leukemia lawyers are currently investigating the link between leukemia and Remicade treatment in both adults and children. It’s long been known that Tumor Necrosis Factor (TNF) blockers, like Remicade, may increase risks for cancer, including leukemia. Since 2008, the U.S. Food & Drug Administration (FDA) has issued several warnings regarding the association between cancer, including leukemia, and TNF blockers like Remicade.
If you or someone you love were diagnosed with leukemia while being treated with Remicade, filing a Remicade leukemia lawsuit may enable you to obtain compensation for your medical bills, lost wages, pain and suffering and other damages. The Remicade side effect lawyers at Parker Waichman LLP are offering free legal evaluations to victims of Remicade leukemia. To learn more about the legal options available to you, please contact our Enbrel leukemia lawyers today.
Remicade and Leukemia
Remicade is an injectable drug used to relieve the symptoms of certain autoimmune disorders including:
- Rheumatoid arthritis that is also being treated with methotrexate.
- Crohn’s disease in adults and children 6 years of age or older that has not improved when treated with other medications.
- Ulcerative colitis in adults and children 6 years of age or older that has not improved when treated with other medications.
- Ankylosing spondylitis
- Psoriatic arthritis
Remicade works by blocking the action of TNF-alpha, a substance in the body that causes inflammation. However, TNF-alpha also helps prevent the formation of tumors and other malignancies.
In June 2008, the FDA announced it was investigating a possible increased risk of cancer in children and young adults treated with TNF blockers, including Remicade. The agency said at the time it had received 30 reports of lymphoma leukemia, melanoma, and solid organ cancers occurring in children and adolescents treated with TNF blockers.
Just a little over a year later, in August 2009, the FDA announced that warnings regarding leukemia and other cancers would be added to labels for all TNF blockers, including:
- Updates to the Boxed Warning to alert healthcare professionals of an increased risk of lymphoma and other malignancies in children and adolescents treated with TNF blockers.
- An update to the Warnings section of the drugs’ labels described reported cases of leukemia in adults, adolescents, and children.
- Changes to the Warnings section of the labeling also included additional information on malignancies in children and adolescents.
According to the FDA, a total of 48 cancers, including leukemia, had been reported among children being treated with TNF blockers. Of the 48 cancer cases, 11 involved deaths.
For leukemia specifically, the FDA’s review uncovered 147 post-marketing reports of leukemia in adults, children and adolescents using TNF blockers. The most frequently reported leukemia types included:
- acute myeloid leukemia (44 cases)
- chronic lymphocytic leukemia (31 cases)
- and chronic myeloid leukemia (23 cases)
Four reports to the FDA involved pediatric leukemia cases, and 30 deaths were reported.